Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Effect of intravitreal bevacizumab on diabetic macular edema during phacoemulasification surgery in diabetic patients who underwent grid or/and panretinal laser photocoagulation

Poster Details

First Author: M.Demir TURKEY

Co Author(s):    D. Guven   Y. Sendul   A. Olgun   Y. Barac     

Abstract Details


To evaluate the results of phacoemulsification combined with injection of 1.25 mg intravitreal bevacizumab in diabetic patients.


Sisli Hamidiye Etfal Training and Research Hospital/ Istanbul/ Turkey


Data of patients who underwent phacoemulsification and received 1.25 mg/0.05 mL intravitreal bevacizumab for diabetic macular edema (DME) were enrolled. Preoperative and postoperative (at 1 month) best corrected visual acuity (BCVA, in snellen) and central macular thickness (CMT) were compared. All cataract surgeries were performed through clear corneal incisions and bevacizumab injections were performed upper temporal area at 3.5 mm from limbus at the end of phacoemulsification. All participants were received grid/or/and pan retinal laser photocoagulation for diabetic retinopathy. Patients with ischemic and/or tractional macular edema, retinal vein occlusion, level of HbA1c>7%, and underwent complicated phacoemulsification were excluded.


This retrospective study included 28 eyes of 27 (16 female, 11 male, mean age: 68.4±8.5 year) patients who underwent uncomplicated phacoemulsification and received 1.25 mg intravitreal bevacizumab for DME. Mean preopreative BCVA was 0.11 and mean CMT was 418 ± 110 µm. Postoperative values of BCVA and CMT were 0.32 and 289 ± 76 µm, respectively.


Improvements in BCVA (p<0.001) and in CMT (p<0.001) were significant after phacoemulsification surgery and received 1.25 mg/ 0.05 mL bevacizumab that injected at the end of surgery in patients who had cataract and coexisting DME

Financial Disclosure:


Back to Poster listing